TELA Bio, Inc. TELA
NASDAQ · United States · Health Technology
$1.14-0.11 (-8.80%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency programMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today. “On behalf of the Board and management team, I woul
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Despite a 4% revenue dip, TELA Bio Inc (TELA) sees strong international growth and improved gross margins while executing a cost-reduction plan to extend its cash runway.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.